CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals , Inc. /quotes/zigman/92812/delayed/quotes/nls/auxl AUXL -2.67% , a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim® testosterone gel. Auxilium’s revised financial guidance is as follows ($ millions):
Help employers find you! Check out all the jobs and post your resume.
